A

coalition of institutional investors is submitting shareholder proposals to demand several drug makers compile reports about the risks created by high prices and, in some cases, also examine the extent to which pricing strategies propel executive compensation.

The move, which is being led by the Interfaith Center for Corporate Responsibility, is an attempt to go beyond similar efforts in years past that largely — and unsuccessfully — tried to force drug makers to justify and explain their pricing.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.